Supplementary Tables S1-S10 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from <i>PLAG1</i>-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors

Suppl. Table S1. Clinicopathologic features of new and published cases of EWSR1/FUS::POU5F1-rearranged MET Suppl. Table S2. Clinicopathologic features of new and published cases of SS18::PBX1/3-rearranged MET Suppl. Table S3. Clinicopathologic features of new and published cases of EWSR1::KLF15-rearranged MET Suppl. Table S4. Clinicopathologic features of new and published cases of EWSR1/FUS::KLF17-rearranged MET Suppl. Table S5. Clinicopathologic features of new and published cases of EWSR1::ZNF444-rearranged MET Suppl. Table S6. Clinicopathologic features of new and published cases of EWSR1::PBX1/3-rearranged MET Suppl. Table S7. Clinicopathologic features of new and published cases of PLAG1-altered MET Suppl. Table S8. Clinicopathologic summary of fusion-positive myoepithelial tumors (new and published cases) Suppl. Table S9. Significant differentially methylated regions: ENT and cutaneous PLAG1-rearranged vs FET-rearranged myoepithelial tumors Suppl. Table S10. Univariate and Multivariate Survival Analysis for Disease-specific Survival (DSS) and Progression-free Survival (PFS)补充表S1：新增及已发表的EWSR1/FUS::POU5F1重排MET病例的临床病理特征 补充表S2：新增及已发表的SS18::PBX1/3重排MET病例的临床病理特征 补充表S3：新增及已发表的EWSR1::KLF15重排MET病例的临床病理特征 补充表S4：新增及已发表的EWSR1/FUS::KLF17重排MET病例的临床病理特征 补充表S5：新增及已发表的EWSR1::ZNF444重排MET病例的临床病理特征 补充表S6：新增及已发表的EWSR1::PBX1/3重排MET病例的临床病理特征 补充表S7：新增及已发表的PLAG1改变型MET病例的临床病理特征 补充表S8：融合基因阳性肌上皮瘤（新增及已发表病例）的临床病理总结 补充表S9：ENT与皮肤PLAG1重排型及FET重排型肌上皮瘤的显著差异甲基化区域 补充表S10：疾病特异性生存期（Disease-specific Survival, DSS）与无进展生存期（Progression-free Survival, PFS）的单因素及多因素生存分析